Today: 8 June 2026
Zip Co stock ends week up 4% as traders turn to Feb results and US growth
10 January 2026
1 min read

Zip Co stock ends week up 4% as traders turn to Feb results and US growth

Sydney, Jan 10, 2026, 17:40 AEDT — Market closed

Zip Co shares finished the week higher, closing at A$3.56 on Friday, up 4.1% from the prior close.

The move followed a bigger jump a day earlier, when the stock rose 7.2% even as no fresh company news surfaced in the session commentary.

Why it matters now: the buy-now, pay-later lender is heading into its half-year results, due on Feb. 19, a scheduled update that has become the next hard date for investors in the name.

On Friday, Zip traded between A$3.425 and A$3.62, with about 18.0 million shares changing hands, according to Yahoo Finance data.

Zip’s investor site shows its most recent ASX announcement was a “change in substantial holding” filed on Jan. 2. Zip

In its October quarterly update, Zip reported record cash EBTDA — earnings before tax, depreciation and amortisation — of A$62.8 million and said it had lifted its on-market buyback to A$100 million. “Zip continues to deliver sustainable, profitable growth at scale,” CEO Cynthia Scott said. Zip

The company has also leaned harder on the United States for growth. Last year, Zip said it was weighing a secondary U.S. listing as it pointed to stronger earnings and a stepped-up U.S. outlook.

Still, the downside case sits close. BNPL — “buy now, pay later” — firms face tighter rules as regulators push them toward credit-style checks, a shift that can squeeze volumes at the margin and raise compliance costs. Reuters

Stock Market Today

  • Asian Shares Fall as Big Tech Slump Hits Global Markets Amid Middle East Tensions
    June 8, 2026, 9:22 AM EDT. Asian shares dropped sharply Monday following Wall Street's worst day since October, driven by a steep decline in the technology sector. South Korea's Kospi plunged 8.3%, led by a 10.2% fall in Samsung Electronics and a 7.7% drop in SK Hynix. Japan's Nikkei 225 declined 3.9%. Wall Street futures showed early gains with Nasdaq up 1.2%. Meanwhile, oil prices surged due to renewed conflict between Israel and Iran, with Brent crude rising to $94.21 a barrel after overnight strikes. The conflict, ongoing since February, continues to disrupt global energy markets and supply chains. European shares showed mixed results, with Germany's DAX down 0.4% and Britain's FTSE 100 up 0.2%. The evolving geopolitical tensions and technology sector weakness underscore global market volatility.

Latest articles

Plug Power Stock Faces a Make-or-Break Week After Friday’s 10% Drop

Plug Power Stock Faces a Make-or-Break Week After Friday’s 10% Drop

8 June 2026
Plug Power rose 2.95% to $3.31 in Monday pre-market trading after a $39.2 million federal tax credit sale tied to its St. Gabriel hydrogen facility, as investors await CEO Jose Luis Crespo’s June 11 update on liquidity and asset sales amid ongoing losses and a recent 10.69% stock drop.
ABAT Shares Jump on DOE’s $115M Lithium Grant Return

ABAT Shares Jump on DOE’s $115M Lithium Grant Return

8 June 2026
American Battery Technology Co shares soared 29.58% to $4.03 premarket after the U.S. Department of Energy fully reinstated a $115 million grant for its Nevada lithium refinery, restoring federal funding for the Tonopah Flats Lithium Project with no change to awarded funds or milestones, though risks remain from permitting, financing, and volatile lithium prices.
NANO Nuclear Stock Bounces, Investors Eye What’s Next

NANO Nuclear Stock Bounces, Investors Eye What’s Next

8 June 2026
NANO Nuclear Energy jumped 7.8% to $25.40 in premarket trading after a 9.9% Friday drop, as traders weighed fresh insider sales filings and recent regulatory progress on its KRONOS microreactor project; the company held $568.7 million in cash as of March 31, but faces sector-wide volatility and execution risks.
Nurix Shares Jump Premarket on Roche $2.3 Billion Cancer Drug Deal

Nurix Shares Jump Premarket on Roche $2.3 Billion Cancer Drug Deal

8 June 2026
Nurix soared 20.4% to $17.62 premarket after Roche agreed to pay $700 million up front in a bexobrutideg collaboration worth up to $2.3 billion, a major cash boost and external validation for Nurix’s lead blood cancer drug ahead of a planned Phase 3 trial, with Roche’s clinical and commercial backing now in play.
Lululemon stock drops nearly 4% as tariff ruling stays unresolved — what to watch next
Previous Story

Lululemon stock drops nearly 4% as tariff ruling stays unresolved — what to watch next

Rio Tinto stock slides on Glencore merger talks as Feb 5 takeover deadline looms
Next Story

Rio Tinto stock slides on Glencore merger talks as Feb 5 takeover deadline looms

Go toTop